Form 8-K - Current report:
SEC Accession No. 0001815776-24-000049
Filing Date
2024-07-15
Accepted
2024-07-15 08:22:04
Documents
15
Period of Report
2024-07-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lenz-20240714.htm   iXBRL 8-K 31571
2 EX-99.1 exhibit991-ridgeback8xk.htm EX-99.1 10053
6 imagea.jpg GRAPHIC 1629
  Complete submission text file 0001815776-24-000049.txt   178871

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lenz-20240714.xsd EX-101.SCH 1889
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lenz-20240714_lab.xml EX-101.LAB 23433
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lenz-20240714_pre.xml EX-101.PRE 13570
18 EXTRACTED XBRL INSTANCE DOCUMENT lenz-20240714_htm.xml XML 3126
Mailing Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014
Business Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014 858-925-7000
LENZ Therapeutics, Inc. (Filer) CIK: 0001815776 (see all company filings)

EIN.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40532 | Film No.: 241115912
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)